GLP-1 receptor agonists and dual agonists such as tirzepatide changed obesity and diabetes care because large trials measured what marketing usually only promises: body weight, heart events, and what happens when the drug stops. This hub is the evidence map — what the trials actually showed, what they did not, and where consumer language runs ahead of the data.
Key facts
- In adults with overweight or obesity without diabetes, once-weekly semaglutide produced substantially greater weight loss than placebo in the STEP 1 trial.1
- Tirzepatide, a dual GIP/GLP-1 agonist, produced large mean weight reductions versus placebo in SURMOUNT-1.6
- SELECT found that semaglutide reduced major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease without diabetes.7
- When semaglutide was stopped after weight loss, much of the lost weight returned in STEP 4 — these are not “one-and-done” treatments in the trial data.4
- Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are common in the trials and are a primary reason people discontinue.16
- These drugs are not a substitute for evaluation of other causes of weight change, and trial populations are not “everyone who wants to lose weight.”
Start here
Semaglutide evidence
STEP program weight trials, SELECT cardiovascular outcomes, and what happens after stopping.
Tirzepatide evidence
SURMOUNT obesity results, how dual agonism differs from GLP-1 alone, and open questions.
GLP-1 and menopause
What research exists when midlife weight change, HRT, and incretin drugs overlap — and what does not.
How we grade this
Why a large outcomes trial outranks an influencer anecdote, and how every grade is computed.
What these drugs are
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic an incretin hormone that affects insulin secretion, glucagon, gastric emptying, and appetite signaling. Semaglutide is a GLP-1 receptor agonist studied for type 2 diabetes and for chronic weight management. Tirzepatide activates both GIP and GLP-1 receptors and has been studied for type 2 diabetes and obesity.69
Brand names circulate faster than trial names. What matters for evidence is the active drug, the population enrolled, the outcome measured, and the duration of follow-up — not the social-media shorthand.
Weight loss: what the major trials measured
STEP 1 enrolled adults with overweight or obesity without diabetes and compared once-weekly semaglutide with placebo, both with lifestyle intervention. Mean weight loss was substantially greater with semaglutide than with placebo at 68 weeks.1
STEP 2 tested the same drug class question in adults who already had type 2 diabetes — a group that typically loses less weight on anti-obesity drugs than people without diabetes. Semaglutide still outperformed placebo on weight, with the expected diabetes-care context layered on top.2
STEP 3 added intensive behavioral therapy; semaglutide still produced greater weight loss than placebo plus the same behavioral package.3 STEP 5 extended follow-up to two years and showed that weight reduction could be maintained with continued treatment relative to placebo.5
SURMOUNT-1 enrolled adults with obesity or overweight plus a weight-related condition, without diabetes, and compared tirzepatide with placebo. Mean weight reductions with tirzepatide were large and dose-related in the trial design; gastrointestinal adverse events were again frequent.6
| Trial program | Drug class | Core question answered |
|---|---|---|
| STEP 1–5 (semaglutide) | GLP-1 RA | Weight loss and maintenance vs placebo in defined adult populations15 |
| SURMOUNT-1 (tirzepatide) | Dual GIP/GLP-1 | Weight loss vs placebo without diabetes6 |
| SURPASS-2 (tirzepatide vs semaglutide) | Head-to-head in T2D | Glycemic and weight endpoints in type 2 diabetes, not a pure obesity trial9 |
| SELECT (semaglutide) | GLP-1 RA | Cardiovascular events in overweight/obesity with CVD, no diabetes7 |
| SUSTAIN-6 (semaglutide) | GLP-1 RA | Cardiovascular outcomes in type 2 diabetes at high CV risk8 |
Stopping is part of the evidence
STEP 4 is the trial most people never hear in a sales conversation. After an initial run-in on semaglutide, participants were randomized to continue the drug or switch to placebo. Those switched to placebo regained a substantial fraction of the weight they had lost; those who continued maintained more of the reduction.4
That result does not mean “you can never stop.” It means the honest framing is chronic disease management for many people, not a short cosmetic course. Any plan that assumes permanent weight change after a few months of drug alone is arguing with STEP 4, not with a lifestyle blog.
Cardiovascular outcomes are not the same as “heart healthy”
SUSTAIN-6 showed that among people with type 2 diabetes at high cardiovascular risk, semaglutide reduced major adverse cardiovascular events compared with placebo.8 SELECT extended the cardiovascular story to people with overweight or obesity and pre-existing cardiovascular disease without diabetes: semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.7
These are specific trial populations with specific endpoints. They are not a license to claim that every person taking a GLP-1 drug for aesthetic weight loss is buying proven heart protection. SELECT required established cardiovascular disease; it did not enroll healthy people chasing a clothing size.
Where the evidence is strong, and where it is not
| Claim | What the evidence supports |
|---|---|
| Produces clinically meaningful weight loss vs placebo in eligible adults | Strongly supported for semaglutide (STEP) and tirzepatide (SURMOUNT-1)16 |
| Weight regain is common after stopping | Supported by randomized withdrawal design (STEP 4)4 |
| Reduces major CV events in defined high-risk groups | Supported in T2D (SUSTAIN-6) and in obesity with CVD without diabetes (SELECT)78 |
| Gastrointestinal adverse effects are common | Consistently reported across obesity trials16 |
| Safe “shortcut” for anyone who wants to lose weight without medical supervision | Not supported; trial eligibility, contraindications, and monitoring exist for a reason |
| Preserves all lean mass / is free of body-composition tradeoffs | Not a settled free lunch; weight loss includes fat and some lean tissue — individual monitoring matters |
| Works as a lifestyle replacement with no behavior context | Not how the pivotal trials were run; lifestyle intervention was part of the protocol1 |
Risks and practical realities the trials keep reporting
Nausea, vomiting, diarrhea, and constipation dominate the adverse-event tables. Gallbladder-related events and other risks appear in labels and trial reports; rare but serious events are why these remain prescription therapies with labeled warnings rather than over-the-counter supplements.16
Supply shortages, compounding, and “research peptide” lookalikes are a separate regulatory problem from the efficacy trials. A randomized trial of pharmaceutical-grade drug says nothing about an unregulated product sold online. Hormone Hero treats compounded or grey-market products as a compliance and safety topic, not as interchangeable with the drugs studied in STEP and SURMOUNT.
Questions worth asking
- Do I meet a labeled indication, or am I being sold a wellness product with a trial name attached?
- What is the plan if I stop — and have I been shown the STEP 4 regain data?
- What monitoring is planned for side effects, nutrition, and other medications?
- If heart risk is part of the pitch, do I actually match SELECT or SUSTAIN-6 populations?
- Is this pharmaceutical supply, or a compounded/unregulated substitute?
Frequently asked questions
Are Ozempic, Wegovy, and Mounjaro the same thing?
No. They are brand products for different labeled uses and, in tirzepatide’s case, a different mechanism (dual GIP/GLP-1). Semaglutide is the active drug in more than one brand; tirzepatide is a different molecule. Trial results attach to the drug and the studied population, not to internet nicknames.
Do I keep the weight off after stopping?
In STEP 4, people who switched from semaglutide to placebo regained a large share of lost weight compared with those who continued the drug. Maintenance strategies exist, but “I will take it for three months and be done” is not what that trial supports as a default expectation.
Do these drugs protect the heart for everyone?
No. SELECT and SUSTAIN-6 showed cardiovascular benefit in specific high-risk groups under trial conditions. That is important evidence. It is not the same as a universal heart-protection claim for every person using a GLP-1 drug for weight loss.
Is tirzepatide “better” than semaglutide?
Head-to-head data exist in type 2 diabetes (SURPASS-2), and obesity programs for each drug show large average weight losses versus placebo. “Better” depends on the outcome, the person, tolerability, access, and labeled use — not a single influencer chart. Compare the actual trial populations before treating a mean percentage as a personal guarantee.
Can I use a research peptide or compounded copy instead?
The pivotal trials used regulated pharmaceutical products. Unregulated or compounded copies are not interchangeable with those products on the strength of STEP or SURMOUNT. Regulatory status and product quality are separate from efficacy claims in NEJM and JAMA.
The bottom line
GLP-1 and dual agonists earned their reputation the hard way: multi-thousand-person trials, hard endpoints, and uncomfortable regain data when treatment stops. Used in the populations studied, they can produce large average weight loss and, in defined high-risk groups, fewer major cardiovascular events.
What they did not earn is magical thinking. They do not erase the need for medical judgment, they do not make unregulated lookalikes evidence-based, and they do not turn a chronic metabolic problem into a short cosmetic project. Read the trials; ignore the nickname economy.